摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(6Z,8S,8aS)-8-methyl-6-{(2R,4E)-2-methyl-5-[(4R,5R)-2,2,5-trimethyl-1,3-dioxolan-4-yl]-4-hexenylidene}octahydro-8-indolizinol | 119269-59-9

中文名称
——
中文别名
——
英文名称
(6Z,8S,8aS)-8-methyl-6-{(2R,4E)-2-methyl-5-[(4R,5R)-2,2,5-trimethyl-1,3-dioxolan-4-yl]-4-hexenylidene}octahydro-8-indolizinol
英文别名
(6Z,8S,8aS)-8-methyl-6-[(E,2R)-2-methyl-5-[(4R,5R)-2,2,5-trimethyl-1,3-dioxolan-4-yl]hex-4-enylidene]-1,2,3,5,7,8a-hexahydroindolizin-8-ol
(6Z,8S,8aS)-8-methyl-6-{(2R,4E)-2-methyl-5-[(4R,5R)-2,2,5-trimethyl-1,3-dioxolan-4-yl]-4-hexenylidene}octahydro-8-indolizinol化学式
CAS
119269-59-9
化学式
C22H37NO3
mdl
——
分子量
363.541
InChiKey
VFPFYUAOMAYEHW-HNWZZPOLSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.2
  • 重原子数:
    26
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.82
  • 拓扑面积:
    41.9
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    聚光毒素生物碱的趋同方法。(+)-铝毒素A,B和225F的不对称全合成。
    摘要:
    利用Pd(0)催化的均烯酸有机锌和乙烯基碘化物之间的交叉偶联反应,已经开发了一种通用的会聚方法来制备pumiliotoxin生物碱。通过将手性甲硅烷基亚烷基19高度立体选择性地加成到(S)-乙酰基吡咯烷中,然后钯催化的分子内羰基化键合环化序列,合成了用作常见关键中间体的(Z)-碘亚烷基吲哚并吡啶34。该合成过程允许(+)-pumiliotoxin 225F的第一个全合成。将获得的中间体(Z)-碘亚烷基吲哚并吡啶34转化为均烯丙基氯化锌衍生物,并使用Pd(PPh(3))(4)催化剂与(E)-乙烯基碘42进行均烯丙基-乙烯基交叉偶联,得到带有1,5-二烯侧链的交叉偶联产物47。
    DOI:
    10.1021/jo0200466
  • 作为产物:
    描述:
    (4R,5R)-4-[(E)-2-iodo-1-methylethenyl]-2,2,5-trimethyl-1,3-dioxolane 在 triethylamine tris(hydrogen fluoride) 、 三乙胺 、 zinc(II) chloride 作用下, 以 四氢呋喃乙醚乙腈 为溶剂, 反应 26.5h, 生成 (6Z,8S,8aS)-8-methyl-6-{(2R,4E)-2-methyl-5-[(4R,5R)-2,2,5-trimethyl-1,3-dioxolan-4-yl]-4-hexenylidene}octahydro-8-indolizinol
    参考文献:
    名称:
    聚光毒素生物碱的趋同方法。(+)-铝毒素A,B和225F的不对称全合成。
    摘要:
    利用Pd(0)催化的均烯酸有机锌和乙烯基碘化物之间的交叉偶联反应,已经开发了一种通用的会聚方法来制备pumiliotoxin生物碱。通过将手性甲硅烷基亚烷基19高度立体选择性地加成到(S)-乙酰基吡咯烷中,然后钯催化的分子内羰基化键合环化序列,合成了用作常见关键中间体的(Z)-碘亚烷基吲哚并吡啶34。该合成过程允许(+)-pumiliotoxin 225F的第一个全合成。将获得的中间体(Z)-碘亚烷基吲哚并吡啶34转化为均烯丙基氯化锌衍生物,并使用Pd(PPh(3))(4)催化剂与(E)-乙烯基碘42进行均烯丙基-乙烯基交叉偶联,得到带有1,5-二烯侧链的交叉偶联产物47。
    DOI:
    10.1021/jo0200466
点击查看最新优质反应信息

文献信息

  • A naturally occurring erythro diastereomer of pumiliotoxin b
    作者:H.M. Garraffo、M.W. Edwards、T.F. Spande、J.W. Daly、Larry E. Overman、C. Severini、V. Erspamer
    DOI:10.1016/s0040-4020(01)86205-0
    日期:1988.1
  • GARRAFFO, H. M.;EDWARDS, M. W.;SPANDE, T. F.;DALY, J. W.;OVERMAN, LARRY E+, TETRAHEDRON, 44,(1988) N 22, C. 6795-6800
    作者:GARRAFFO, H. M.、EDWARDS, M. W.、SPANDE, T. F.、DALY, J. W.、OVERMAN, LARRY E+
    DOI:——
    日期:——
  • Convergent Approach to Pumiliotoxin Alkaloids. Asymmetric Total Synthesis of (+)-Pumiliotoxins A, B, and 225F
    作者:Sakae Aoyagi、Shintaro Hirashima、Kosuke Saito、Chihiro Kibayashi
    DOI:10.1021/jo0200466
    日期:2002.8.1
    (Z)-iodoalkylidene indolizidine 34, which served as a common key intermediate, was synthesized through highly stereoselective addition of the chiral silylallene 19 to (S)-acetylpyrrolidine followed by a palladium-catalyzed intramolecular carbonylation[bond]cyclization sequence. This synthetic process allowed the first total synthesis of (+)-pumiliotoxin 225F. The intermediate (Z)-iodoalkylidene indolizidine 34 obtained
    利用Pd(0)催化的均烯酸有机锌和乙烯基碘化物之间的交叉偶联反应,已经开发了一种通用的会聚方法来制备pumiliotoxin生物碱。通过将手性甲硅烷基亚烷基19高度立体选择性地加成到(S)-乙酰基吡咯烷中,然后钯催化的分子内羰基化键合环化序列,合成了用作常见关键中间体的(Z)-碘亚烷基吲哚并吡啶34。该合成过程允许(+)-pumiliotoxin 225F的第一个全合成。将获得的中间体(Z)-碘亚烷基吲哚并吡啶34转化为均烯丙基氯化锌衍生物,并使用Pd(PPh(3))(4)催化剂与(E)-乙烯基碘42进行均烯丙基-乙烯基交叉偶联,得到带有1,5-二烯侧链的交叉偶联产物47。
查看更多

同类化合物

(6E,7R,8R,8aS)-6-[(4E,6S)-6-羟基-2,5-二甲基辛-4-烯-1-亚基]-8-甲基八氢中氮茚-7,8-二醇 pumiliotoxin B pumiliotoxin B (8R,8αS)-8-hydroxy-8-methyl-6-((Z)-2(R)-methyl-hexylidene)octahydroindolizin-7-one erythro pumiliotoxin PTX-B (6Z,8S,8aS)-6-[(2R,4E,6S)-6-(benzyloxy)-2,5-dimethyl-4-octenylidene]-8-{[tert-butyl(dimethyl)silyl]oxy}-8-methyloctahydroindolizine (6Z,8S)-6-[(E,6S)-6-hydroxy-2,5-dimethyloct-4-enylidene]-8-methyl-1,2,3,5,7,8a-hexahydroindolizin-8-ol (8R,8aS,6E)-8-Hydroxy-8-methyl-[(2R,4E,6S)-2,5-dimethyl-6-benzyloxymethyloxy-4-octenylidene]octahydroindolizin-7-done (8R,8aS)-8-hydroxy-6-[(E,2R,6S)-1-hydroxy-2,5-dimethyl-6-(phenylmethoxymethoxy)oct-4-enyl]-8-methyl-1,2,3,5,6,8a-hexahydroindolizin-7-one (+)-Allopumiliotoxin 323B' Pumiliotoxin 237A (1R,2R,9aS)-1-(benzyloxy)-2-hydroxy-3(E)-isobutylidene-1-methyloctahydroquinolizine (7S,8R,8aS)-8-(benzyloxy)-7-hydroxy-8-methyl-6-(E)-<(2R)-2-methylpentylidene>octahydroindolizidine (+)-allopumiliotoxin 267 A (+)-Pumiliotoxin 251D (3E)-(5S,6S)-5-hydroxy-3-[(R)-2-methylhexylidene]-5-methylazabicyclo[4.3.0]nonan-2-one (8S,8aS)-8-hydroxy-8-methyl-6(Z)-<2(R)-methylhexylidene>octahydro-5-indolizidinone (8S,8aS)-8-hydroxy-8-methyl-(6Z)-<(2R,4E,6S)-6-(benzyloxy)-2,5-dimethyl-4-octenylidene>octahydroindolizidine (+)-(15S)-pumiliotoxin A (+)-allopumiliotoxin 339A (6E,7S,8R,8aS)-8-methyl-6-[(E,2R)-2-methyl-5-[(4R,5R)-2,2,5-trimethyl-1,3-dioxolan-4-yl]hex-4-enylidene]-8-phenylmethoxy-1,2,3,5,7,8a-hexahydroindolizin-7-ol (+)-allopumiliotoxin 339 B (7R,8R,8aS)-8-(benzyloxy)-7-hydroxy-6(Z)-<6(R),7(R)-(isopropylidenedioxy)-2(R),5-dimethyl-4(E)-octenylidene>-8-methyloctahydroindolizine (+)-homopumiliotoxin 223G (6Z)-8-methyl-6-(2-methylhexylidene)-1,2,3,5,7,8a-hexahydroindolizine-7,8-diol (7R,8R,8aS,E)-6-((2R,6R,7R,E)-6,7-Dihydroxy-2,5-dimethyloct-4-en-1-ylidene)-8-methyloctahydroindolizine-7,8-diol (8S,8aS)-6-[2,2-Dimethyl-hex-(Z)-ylidene]-8-methyl-octahydro-indolizin-8-ol (R,4E,8E)-8-((7R,8R,8aS)-7,8-Dihydroxy-8-methylhexahydroindolizin-6(5H)-ylidene)-4,7-dimethyloct-4-en-3-one (4E,7R,8Z)-8-((1S,9aS)-1-Hydroxy-1-methyltetrahydro-1H-quinolizin-3(2H,4H,6H)-ylidene)-4,7-dimethyloct-4-ene-2,3-diol (1S,9aS,Z)-3-((2R,E)-7-Hydroxy-2,5-dimethyloct-4-en-1-ylidene)-1-methyloctahydro-1H-quinolizin-1-ol (1S,9aS,Z)-3-((2R,E)-6-Hydroxy-2,5-dimethylnon-4-en-1-ylidene)-1-methyloctahydro-1H-quinolizin-1-ol (8S,8aS,Z)-6-((R,4E,6E)-2,5-Dimethylocta-4,6-dien-1-ylidene)-8-methyloctahydroindolizin-8-ol (8S,Z)-6-((2R,E)-6-Hydroxy-2,5-dimethylhept-4-en-1-ylidene)-8-methyloctahydroindolizin-8-ol (R,Z)-6-((8S,8aS)-8-Hydroxy-8-methylhexahydroindolizin-6(5H)-ylidene)-5-methylhexan-2-one (8S,8aS,Z)-6-((2R)-4-Hydroxy-2-methylpentylidene)-8-methyloctahydroindolizin-8-ol (1S,9aS,Z)-3-((S)-3-Hydroxy-2-methylpropylidene)-1-methyloctahydro-1H-quinolizin-1-ol (8S,8aS,Z)-8-Methyl-6-((R)-2-methylpentylidene)octahydroindolizin-8-ol (6E)-8-methyl-6-(2-methylhexylidene)-8-phenylmethoxy-1,2,3,5,7,8a-hexahydroindolizin-7-ol (6Z)-6-[(E)-6-hydroxy-2,5-dimethyloct-4-enylidene]-8-methyl-1,2,3,5,7,8a-hexahydroindolizin-8-ol (8S,8aS,Z)-6-((2R)-5-Hydroxy-2-methylhexylidene)-8-methyloctahydroindolizin-8-ol Allopumiliotoxin 253a (8R,8aS,E)-6-((2R,6R,E)-6-Hydroxy-2,5-dimethyloct-4-en-1-ylidene)-8-methyloctahydroindolizine-7,8-diol Pumiliotoxin 309a (6E)-8-methyl-6-(2-methylhexylidene)-1,2,3,5,7,8a-hexahydroindolizine-7,8-diol (+)-Pumiliotoxin B 8-Methyl-6-(2-methylhexylidene)-8-phenylmethoxy-1,2,3,5,7,8a-hexahydroindolizin-7-ol (1S,9aS,Z)-3-((2R)-6-Hydroxy-2,5-dimethyloctylidene)-1-methyloctahydro-1H-quinolizin-1-ol (8S,8aS,Z)-6-((R)-7-Hydroxy-2-methylheptylidene)-8-methyloctahydroindolizin-8-ol (8S,8aS,Z)-6-((R,E)-2,5-Dimethyloct-4-en-1-ylidene)-8-methyloctahydroindolizin-8-ol (8S,8aS,Z)-8-Methyl-6-((R,E)-2-methyl-5-((4R,5S)-2,2,5-trimethyl-1,3,2-dioxasilolan-4-yl)hex-4-en-1-ylidene)octahydroindolizin-8-ol